price transparency
publication date
Pharma
Top CA Dems Clash Over How to Rein In PBMs
As prescription drug prices continue to spiral and federal efforts to control them stall, state lawmakers are focusing on PBMs.
Revenue Cycle
With Trump on the Way, Advocates Look to States to Pick Up Medical Debt Fight
But new state initiatives may not be enough to protect Americans from medical debt.
Pharma
PBM Math: Big Chains Are Paid $23.55 To Fill a Blood Pressure Rx. Small Drugstores? $1.51.
Chains are paid well beyond family businesses for many of the same medications.
Revenue Cycle
WEDI Scrutinizes Price Estimates Citing Concerns Over Accuracy
In a letter the organization expresses concern over information unknown to the provider being used to estimate the cost of...
Payer
Contributed Content: 2 Alternatives to Ineffective Prescription Drug Rebates
Prescription drug rebates were once a good idea. Not any more.
Pharma
U.S. $772.5B Pharmacy Spend in 2023 Driven by Weight-Loss Drugs
Prescription drug spending grew by 13.5% in 2023, but drug cost inflation was lower than the CPI.
CFO
Medical Debt Affects Much of America, but Colorado Immigrants Are Hit Especially Hard
The state's overall medical debt burden is lower than most. But racial and ethnic disparities are wider.
Pharma
Indiana AG Sues Drugmakers, PBMs Over High Insulin Prices
The suit says diabetes care costs the Hoosier State $5 billion annually.
Revenue Cycle
Are Health Orgs Delivering on Price Transparency?
Price transparency isn?t just a compliance measure ? it?s become a patient preference.
Pharma
Modest Drug Costs Hikes Predicted for 2024. Drug Expenditures Are a Different Story
One expert believes that drug price increases will fall in line with inflation as measured by the CPI.
HLM Cover Stories
Why Long-Term Care Insurance Falls Short for So Many
For decades, the industry severely underestimated how many policyholders would use their coverage.
Revenue Cycle
3 New Hospitals on CMS' Price Transparency Chopping Block
CMS fined three hospitals for alleged price transparency violations.